TEVJF:OTC-Teva Pharmaceutical Industries Limited (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 16.11

Change

0.00 (0.00)%

Market Cap

USD 20.77B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-12 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MKGAF MERCK Kommanditgesellschaft au..

+5.48 (+4.01%)

USD 58.42B
MKKGY Merck KGaA ADR

+0.19 (+0.68%)

USD 53.54B
HLNCF Haleon plc

-0.23 (-4.12%)

USD 47.19B
TKPHF Takeda Pharmaceutical Co. Ltd.

-1.91 (-6.40%)

USD 46.97B
HNSPF Hansoh Pharmaceutical Group Co..

N/A

USD 20.51B
SDZXF Sandoz Group AG

N/A

USD 17.55B
SDZNY Sandoz Group AG

-0.80 (-1.75%)

USD 16.54B
SWOBY Swedish Orphan Biovitrum AB (p..

N/A

USD 10.30B
IPSEY Ipsen SA ADR

-1.38 (-4.69%)

USD 9.72B
IPSEF Ipsen S.A

N/A

USD 9.21B

ETFs Containing TEVJF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.92% 44% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.92% 44% F 28% F
Trailing 12 Months  
Capital Gain 37.11% 86% B+ 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.11% 86% B+ 80% B-
Trailing 5 Years  
Capital Gain 58.72% 89% A- 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.72% 89% A- 66% D+
Average Annual (5 Year Horizon)  
Capital Gain 18.53% 74% C 68% D+
Dividend Return 18.53% 74% C 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.63% 69% C- 54% F
Risk Adjusted Return 42.46% 93% A 80% B-
Market Capitalization 20.77B 99% N/A 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector